Clinical Trials
Research
Dr. Iram Ahmad, MD, MME
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Jennifer Alyono, MD, MS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Noel Ayoub, MD, MBA
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Fred M. Baik, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Karthik Balakrishnan, MD, MPH, FAAP, FACS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Nikolas Blevins, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Robson Capasso, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Michael Chang, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Kay W. Chang, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Michelle Chen, MD, MHS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Alan G. Cheng, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Edward J. Damrose, MD, FACS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Seth Davis, MD, FACS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Vasu Divi, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Elizabeth Erickson-DiRenzo, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Andrey Finegersh, MD, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Matthew Fitzgerald, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Pedro Gomes de Oliveira, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Stefan Heller, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Katie Hohenberger, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Chris Holsinger, MD, FACS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Peter H. Hwang, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Nancy Jiang, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Grace Kim, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Jennifer Lee, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Jake Lee, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. William Lewis, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Ted Mau, MD, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Uchechukwu Megwalu, MD, MPH
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Kara Meister, MD, FAAP, FACS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Lloyd Minor, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Lindsay Moore, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Sam P. Most, MD, FACS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Eric Nash, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Jayakar V. Nayak, MD, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Teresa Nicolson, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Brian Nuyen, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Dáibhid Ó Maoiléidigh, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Lisa A. Orloff, MD, FACS, FACE
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Zara Patel, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Jon-Paul Pepper, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Anthony J. Ricci, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Nathan Reticker-Flynn, PhD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Douglas Sidell, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Davud Sirjani, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Alyssa Smith, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Konstantina M. Stankovic, MD, PhD, FACS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Heather Starmer, MA CCC-SLP, BCS-S
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Kristen K. Steenerson, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. C. Kwang Sung, MD, MS
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. John B. Sunwoo, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Tristan Tham, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Mai Thy Truong, MD
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.
Dr. Tulio Valdez, MD, MSc
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford is currently accepting patients for this trial. -
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford is currently accepting patients for this trial. -
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Stanford is currently accepting patients for this trial. -
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Stanford is currently accepting patients for this trial. -
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Stanford is currently accepting patients for this trial. -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford is currently accepting patients for this trial. -
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Stanford is currently accepting patients for this trial.